Clinical Implications of Azole Resistance in Aspergillus fumigatus, the Netherlands, 2007-2009

Jan W. M. van der Linden*, Eveline Snelders, Greetje A. Kampinga, Bart J. A. Rijnders, Eva Mattsson, Yvette J. Debets-Ossenkopp, Ed J. Kuijper, Frank H. Van Tiel, Willem J. G. Melchers, Paul E. Verweij

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

343 Citaten (Scopus)

Samenvatting

The prevalence and spread of azole resistance in clinical Aspergillus fumigatus isolates in the Netherlands are currently unknown. Therefore, we performed a prospective nationwide multicenter surveillance study to determine the effects of resistance on patient management strategies and public health. From June 2007 through January 2009, all clinical Aspergillus spp. isolates were screened for itraconazole resistance. In total, 2,062 isolates from 1,385 patients were screened; the prevalence of itraconazole resistance in A. fumigatus in our patient cohort was 5.3% (range 0.8%-9.5%). Patients with a hematologic or oncologic disease were more likely to harbor an azole-resistant isolate than were other patient groups (p

Originele taal-2English
Pagina's (van-tot)1846-1854
Aantal pagina's9
TijdschriftEmerging Infectious Diseases
Volume17
Nummer van het tijdschrift10
DOI's
StatusPublished - okt-2011
Extern gepubliceerdJa

Citeer dit